BCL2 and acute myeloid leukemia: In particular, the Bcl-2 inhibitor venetoclax, which targets mitochondrial anti-apoptotic mechanisms, was shown to improve AML patient survival when combined with cytarabine or 5-azacytidine [3–6], suggesting mitochondria as a pertinent therapeutic target in AML.